Why do we not have an HIV vaccine and how can we make one? .
about
Energetics of the HIV gp120-CD4 binding reactionHost background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted.Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological and overcome the limitations of reductionismPurification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoproteinCD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.Recombinant rabies virus as potential live-viral vaccines for HIV-1.Protein grafting of an HIV-1-inhibiting epitopePolyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.Immune modulation by helminthic infections: worms and viral infections.The homodimer of prostate-specific membrane antigen is a functional target for cancer therapyVaccine-induced cytotoxic T lymphocytes protect against retroviral challenge.Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structureCharacterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope proteinImmunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats.Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same siteMolecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergyDevelopment of HIV/AIDS vaccine using chimeric gag-env virus-like particles.Immunogenicity of the outer domain of a HIV-1 clade C gp120.Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies.HIV-1 neutralizing antibodies: how full is the bottle?
P2860
Q22254716-4E26B3CC-A6EA-48F2-A581-5D1285DAB889Q24531918-A7C40E98-01B9-43D2-8D04-0CC9CDB71AD6Q31016954-D6090AC9-5517-434C-8CED-3730A463F3BDQ31016969-B3DC2F98-79F8-438D-9680-2A55D32C4B61Q33645053-603B3746-6CB3-431F-A348-72C6C59502E1Q33724169-5CAA8985-2E49-47AB-A672-44DA53A80B01Q33803217-FE381AF1-0C24-48BE-BA9A-EBAFC345B7AEQ33804811-BD661DFA-FE33-4226-8E35-C5B9B9B5D5BDQ33806303-D9776CB4-4894-44B2-A9F5-0FBB7A227CC0Q33822395-02668C1A-880F-4DE0-8EF2-9CE27C1432F9Q33839136-08588218-8B8F-497B-B49D-1D62EDBFF585Q34166335-74272D0D-B913-4418-AE7A-03DAB4A98AD8Q34332284-CC34198E-BDD4-42FE-BB86-79C29DC3E45EQ34347265-96D84FBB-CBEA-4A90-BF73-1412474F5384Q34462299-ECD36CCA-D672-4D16-8F8A-6A4A44133B28Q34979735-FD22E34E-7A86-47CD-90A8-DC35FAD5C42BQ34999293-DA8592D7-B984-4B8C-8B9D-52773FE9DFC3Q35101431-11B93D3A-5BC3-4307-918F-ABC4565ADCD5Q35115861-08E61722-9C64-4DAF-8185-16A335810AC7Q35813478-C12590AC-5952-40CB-A136-E05F4F0D9837Q36541239-DC3EFE65-B6BB-40E2-98BD-DADA10CA118BQ36590684-2E7915B4-F492-44F8-9968-3FD687AA36B7Q36689474-CB1B2F11-71BB-47A9-97B2-BD5D05642DADQ36898880-D0B820D7-0DB3-4F77-A10B-63857B0AEF51Q37059997-5B641D17-0877-4110-8771-6F021046F981Q37347813-7BA9EFD1-FD2C-4AE7-A2C3-C7D62AFEBCDBQ39588870-B467591B-69CE-4745-BE89-F47167126208Q39592994-C5E65B12-448A-4063-9C88-459CE67139D3Q39597617-5B0B77A3-1D9A-417B-86C7-380BA229B37EQ39699375-50650820-2E2C-4A79-8F1D-666D2A304161Q39748810-02B637E8-091E-4CCC-9661-E36B6F3C8695Q39789278-A06FE3DD-F8CB-47C8-930B-C2CF495CDE89Q40431993-5040B4D2-98A6-4B24-889A-E97BC657D284Q40957591-7383C5E3-364F-4E1F-90AE-405DC1A1E07DQ41961460-5A7A9E1F-26A9-4062-BC2C-0FE0929DB9F6Q45737326-D42A5229-D323-4E9D-A296-33C9029B5646Q52844823-535341C4-996B-4BC3-A450-0BFF22888AB9
P2860
Why do we not have an HIV vaccine and how can we make one? .
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Why do we not have an HIV vaccine and how can we make one? .
@en
type
label
Why do we not have an HIV vaccine and how can we make one? .
@en
prefLabel
Why do we not have an HIV vaccine and how can we make one? .
@en
P2860
P356
P1433
P1476
Why do we not have an HIV vaccine and how can we make one? .
@en
P2093
P2860
P2888
P304
P356
10.1038/NM0598SUPP-495
P407
P433
P577
1998-05-01T00:00:00Z